Search Results

now acts as a proxy for how well a founding team understands and manages its core risks. ✅ When the Founders often present patents as proof of strength, while investors read them as indicators of risk That uncertainty increases perceived risk, even if the underlying science is compelling. Even if the risk is manageable, not addressing it makes the fundraising process harder. This shift is not about stricter rules, but about earlier and clearer risk assessment .

This is the essence of de-risking GPCR programs through operational excellence. your drug discovery process from a series of disconnected efforts into a seamless, predictable, and de-risked of precise alignment between GPCR scientific milestones  and financial realities creates significant risk Learn to translate your program’s internal operational precision into a compelling, de-risked narrative

In reality, the FDA acts more like a systems-level risk assessor . rationale: Are you selecting the right patient subgroup with a clear justification for the benefit-risk The sooner you understand what they’re optimizing for, the faster you can align your strategy to de-risk scale-up and CMC documentation  in mind You assess safety signals based on their translatability to human risk

Aurélien Rizk About Dr. Aurélien Rizk "Dr. Aurélien Rizk is a scientist and entrepreneur in drug discovery. Aurélien Rizk co-founded Algorizk, a company that created real-time physics simulations for education Aurélien Rizk on the web InterAx Biotech Paul Scherrer Institut The Org LinkedIn Google Scholar Dr. Rizk discussed the differences between academia and the biotech industry, with Aurelien Rizk sharing

Oprea , Thomas Sakmar , Aurelien Rizk & Yaroslav Nikolaev .

metabolism & clearance ✅ PK-PD modeling & therapeutic profiles ✅ Early safety assessments & toxicity risks metabolism & clearance✅ PK-PD modeling & therapeutic profiles✅ Early safety assessments & toxicity risks